SECURE-CODE-WARRIOR
23.7.2024 14:01:30 CEST | Business Wire | Press release
Secure Code Warrior, the global, developer-driven security leader, today announced the availability of SCW Trust Agent – an industry-first solution that assesses the specific security competencies of developers for every code commit. This innovative offering enables CISOs and application security (AppSec) teams to embrace a Secure-by-Design approach with deeper visibility into their organizations’ software development security posture.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240723230392/en/
SCW Trust Agent provides visibility and control to scale developer driven security (Photo: Business Wire)
The launch of SCW Trust Agent follows the company’s rollout of SCW Trust Score, the first industry benchmark that quantifies the security posture of organizations’ developer teams. Both innovations apply over 20 million learning data points collected from 250,000 developers around the world. These deliver quantitative mechanisms that, when paired with Secure Code Warrior’s agile learning platform, become an integral part of an organization’s secure software development lifecycle.
“At Secure Code Warrior, we are unlocking new value for CISOs by giving them an easy-to-deploy solution to measure the health of code commits and visibility into the hundreds of source code repositories in their organization,” said Pieter Danhieux, Co-founder and CEO, Secure Code Warrior. “Our innovations are putting organizations in a better position to bridge the visibility gap between a developer's skill sets and quality of code produced without sacrificing development velocity.”
SCW Trust Agent works seamlessly with any Git-based code repository including GitHub, GitLab, Atlassian Bitbucket and more. With every commit, it looks to see if the developer making it has the prescribed secure code skillset in the commit’s programming language. It uses this information to give a rating on the health of that commit and aggregates these ratings across all of your repositories.
SCW Trust Agent delivers greater control and flexibility for developer gatekeeping. It allows administrators to set up policies and criteria, ensuring developers meet a baseline set of standards and expectations before developing code. For any gaps in developer skills, they can reference the SCW agile learning platform to upskill their language specific knowledge and competencies.
Overall SCW Trust Agent delivers:
- Improved Security Controls: Customize policy configuration based on the sensitivity of project requirements
- Comprehensive Visibility: Actionable insights into the security posture of every commit across all of your code repositories
- Developer-Led Security at Scale: Deliver projects securely at speed - allowing application security teams to focus on the most sensitive security reviews
For more information on SCW Trust Agent, visit: www.scwtrustagent.com
About Secure Code Warrior
Secure Code Warrior is a secure coding platform that sets the standards that keep our digital world safe. We do this by providing the world’s leading agile learning platform that delivers the most effective secure coding solution for developers to learn, apply, and retain software security principles. More than 600 enterprises trust Secure Code Warrior to implement agile learning security programs and ensure the applications they release are free of vulnerabilities.
For more information about Secure Code Warrior, visit www.securecodewarrior.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723230392/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom